New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Paige Lanyon-Roberts

Dr Paige Lanyon-Roberts

The New Oral Medications for Obesity – A Practical Guide for GPs

Dr Terri-Lynne South

Dr Terri-Lynne South

Oral GLP1s – What GPs Need to Know

Dr Katherine Spira

Dr Katherine Spira

Menstrual Migraine

Prof Danny Green

Prof Danny Green

GLP1s and Muscle Mass – What Does the Evidence Show?

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970